Get the Stockscreener App
1.3861
0.36%
0.0061
Pepgen Inc stock is traded at $1.3861, with a volume of 146.51K.
It is up +0.36% in the last 24 hours and down -60.32% over the past month.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.
See More
Previous Close:
$1.38
Open:
$1.33
24h Volume:
146.51K
Relative Volume:
0.51
Market Cap:
$44.98M
Revenue:
-
Net Income/Loss:
$-87.23M
P/E Ratio:
-0.4667
EPS:
-2.97
Net Cash Flow:
$-82.77M
1W Performance:
+7.36%
1M Performance:
-60.32%
6M Performance:
-84.40%
1Y Performance:
-88.93%
1-Day Range:
$1.23
$1.391
1-Week Range:
$1.175
$1.49
52-Week Range:
$1.175
$19.30
Pepgen Inc Stock (PEPG) Company Profile
Name
Pepgen Inc
Sector
Industry
Phone
703-456-8000
Address
1 MARINA PARK DRIVE, SUITE 900, BOSTON
Compare PEPG with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PEPG
Pepgen Inc
|
1.39 | 44.98M | 0 | -87.23M | -82.77M | -2.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.85 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.01 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
651.13 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.49 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.63 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Pepgen Inc Stock (PEPG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-31-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-21-22 | Initiated | H.C. Wainwright | Buy |
Pepgen Inc Stock (PEPG) Latest News
Taking on analysts’ expectations and winning: PepGen Inc (PEPG) - SETE News
PEPG’s 2023 Market Dance: Down -64.64% – Time to Invest? - The InvestChronicle
why PepGen Inc [PEPG] is a Good Choice for Investors After New Price Target of $12.80 - The DBT News
FY2029 Earnings Estimate for PepGen Issued By HC Wainwright - MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc.PEPG - PR Newswire
Market Update: PepGen Inc (PEPG) Sees Negative Movement, Closing at 1.25 - The Dwinnex
HC Wainwright Cuts PepGen (NASDAQ:PEPG) Price Target to $16.00 - MarketBeat
What is HC Wainwright’s Estimate for PepGen FY2025 Earnings? - Defense World
H.C. Wainwright cuts PepGen stock target to $16, maintains Buy rating - Investing.com India
JPMorgan Chase & Co. Increases Holdings in PepGen Inc. (NASDAQ:PEPG) - Defense World
HC Wainwright Lowers PepGen (NASDAQ:PEPG) Price Target to $16.00 - Defense World
PepGen price target lowered to $16 from $26 at H.C. Wainwright - Yahoo Finance
PepGen stock plunges to 52-week low of $1.76 amid market challenges - Investing.com
PepGen continues trials for DMD treatment, addresses safety concerns By Investing.com - Investing.com South Africa
PepGen continues trials for DMD treatment, addresses safety concerns - Investing.com India
PepGen Announces CONNECT Program Updates - Business Wire
PepGen's Duchenne Treatment Hits Roadblock: Key Safety Concerns Emerge - StockTitan
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc.PEPG - PR Newswire
PepGen Inc. (PEPG) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
PepGen stock hits 52-week low at $2.21 amid market challenges - MSN
Barclays PLC Has $189,000 Stake in PepGen Inc. (NASDAQ:PEPG) - Defense World
PepGen stock hits 52-week low at $2.21 amid market challenges By Investing.com - Investing.com South Africa
PepGen Inc. (NASDAQ:PEPG) Short Interest Down 14.1% in December - MarketBeat
PepGen stock hits 52-week low at $2.88 amid market challenges - Investing.com Australia
PepGen stock hits 52-week low at $2.88 amid market challenges By Investing.com - Investing.com South Africa
Jane Street Group LLC Purchases 6,254 Shares of PepGen Inc. (NASDAQ:PEPG) - Defense World
All You Need to Know About PepGen (PEPG) Rating Upgrade to Buy - Yahoo Finance
Barclays PLC Has $189,000 Stock Position in PepGen Inc. (NASDAQ:PEPG) - Defense World
Geode Capital Management LLC Has $3.21 Million Stock Holdings in PepGen Inc. (NASDAQ:PEPG) - Defense World
Wedbush Comments on PepGen’s FY2028 Earnings (NASDAQ:PEPG) - Defense World
Fmr LLC Sells 327,160 Shares of PepGen Inc. (NASDAQ:PEPG) - Defense World
Wedbush Has Bullish Forecast for PepGen FY2028 Earnings - MarketBeat
FDA Pauses PepGen’s DMD Drug Trial in the US - AJMC.com Managed Markets Network
PepGen stock craters 35% on FDA clinical hold - MSN
PepGen (NASDAQ:PEPG) Downgraded by Bank of America to Underperform - Defense World
FDA halts PepGen's DMD trial; ongoing study continues By Investing.com - Investing.com Australia
PepGen stock touches 52-week low at $2.9 amid market challenges - Investing.com
FDA halts PepGen's DMD trial; ongoing study continues - Investing.com India
PepGen shares downgraded to Underperform by BofA amid uncertainty over clinical hold - Investing.com
PepGen stock down 22% on FDA clinical hold (update) (PEPG:NASDAQ) - Seeking Alpha
Novo builds up manufacturing; Pepgen Duchenne trial put on hold - BioPharma Dive
Pepgen Inc Stock (PEPG) Financials Data
Revenue
Net Income
Cash Flow
EPS
Pepgen Inc Stock (PEPG) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mellion Michelle L | Chief Medical Officer |
Jul 24 '24 |
Option Exercise |
10.21 |
201 |
2,052 |
201 |
| Mellion Michelle L | Chief Medical Officer |
Jul 25 '24 |
Sale |
18.06 |
7,571 |
136,741 |
0 |
| Mellion Michelle L | Chief Medical Officer |
Jul 24 '24 |
Sale |
18.01 |
201 |
3,619 |
0 |
| Mellion Michelle L | Chief Medical Officer |
Jul 18 '24 |
Option Exercise |
10.21 |
12,625 |
128,901 |
12,625 |
| Mellion Michelle L | Chief Medical Officer |
Jul 18 '24 |
Sale |
18.20 |
12,625 |
229,804 |
0 |
| Mellion Michelle L | Chief Medical Officer |
Jul 16 '24 |
Option Exercise |
10.21 |
5,901 |
60,249 |
5,901 |
| Mellion Michelle L | Chief Medical Officer |
Jul 12 '24 |
Option Exercise |
10.21 |
3,288 |
33,570 |
3,288 |
| Mellion Michelle L | Chief Medical Officer |
Jul 16 '24 |
Sale |
18.00 |
5,901 |
106,247 |
0 |
| Mellion Michelle L | Chief Medical Officer |
Jul 12 '24 |
Sale |
18.04 |
3,288 |
59,331 |
0 |
| Mellion Michelle L | Chief Medical Officer |
Jul 01 '24 |
Option Exercise |
10.21 |
875 |
8,934 |
875 |
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):